#406
|
||||
|
||||
Êîëëåãè, ïîìîãèòå, ïîæàëóéñòà, â ïåðåâîäå. Äëÿ ìåíÿ â ïîñëåäíåå âðåìÿ êàìíåì ïðåòêíîâåíèÿ ÿâëÿþòñÿ òåðìèíû "Large for gestaional age (LGA)", "Appropriate for gestaional age (AGA)" è "Small for gestational age (SGA)". Ñìûñë è äåôèíèöèÿ ìíå ïîíÿòíû. Ïîäñêàæèòå, ïîæàëóéñòà, òî÷íûé ïåðåâîä ýòèõ òåðìèíîâ íà ðóññêèé ÿçûê, ò.å. êàê ýòè òåðìèíû äîëæíû çâó÷àòü íà ðóññêîì è åñòü ëè ïðèíÿòàÿ àááðåâèàòóðà íà ðóññêîì?
|
#407
|
||||
|
||||
Òàêîå íàãóãëèëà:
"Ïî ñîîòíîøåíèþ ìàññû òåëà è ãåñòàöèîííîãî âîçðàñòà êàê äîíîøåííûõ, òàê è íåäîíîøåííûõ äåòåé ðàçäåëÿþò íà òðè ãðóïïû: • áîëüøèå äëÿ äàííîãî ãåñòàöèîííîãî âîçðàñòà (ÁÃÂ); • ñîîòâåòñòâóþùèå ãåñòàöèîííîìó âîçðàñòó (ÑÃÂ); • ìàëûå äëÿ ãåñòàöèîííîãî âîçðàñòà (ÌÃÂ)." [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Àâòîðû, íå çàìîðà÷èâàÿñü, èñïîëüçóþò "êàëüêó". |
#408
|
||||
|
||||
Áîëüøîå ñïàñèáî! Ñìóùàåò åäèíñòâåííîå - èñòî÷íèê èíôîðìàöèè. Õîòÿ, åñëè âíèçó àâòîð Øàáàëîâ Í.Ï., äóìàþ, ìîæíî ïîëüçîâàòüñÿ ýòèìè òåðìèíàìè.
|
#409
|
|||
|
|||
Íà àãëèöêîì âðîäå ïîíèìàþ ñóòü, à âîò äîõîä÷èâî ïåðåâåñòè íå ïîëó÷àåòñÿ....
graded challenges programs must distribute specimens at least twice per year including a sufficient number of challenges (cases) to ensure adequate assessment of laboratory performance. For programs with 10 or more challenges per event, satisfactory performance requires correct identification of at least 90% of the graded challenges in each testing event. Laboratories with less than 90% correct responses on graded challenges.... |
#410
|
||||
|
||||
Äëÿ ïðîãðàìì ñ 10 è áîëåå çàäàíèÿìè íà êàæäîå òåñòèðîâàíèå, óäîâëåòâîðèòåëüíûì áóäåò ñ÷èòàòüñÿ êàê ìèíèìóì 90% ïðàâèëüíîå âûïîëíåíèå çàäàíèé â êàæäîé ñåðèè òåñòèðîâàíèÿ.
Ëàáîðàòîðèè, ó êîòîðûõ ïðàâèëüíîå âûïîëíåíèå çàäàíèé áóäåò ìåíåå 90%...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#411
|
|||
|
|||
Ñïàñèáî, äîïåð, ÷òî challenges (cases) ó íèõ íå "ñëîæíûé ñëó÷àé", à ïðîñòî "çàäà÷à".
|
#412
|
||||
|
||||
graded challenges ÿ áû ïåðåâåëà êàê "çàäà÷è/çàäàíèÿ/òåñòû ðàçëè÷íîé ñòåïåíè ñëîæíîñòè", íî íàäî îðèãèíàëüíûé òåêñò ãëÿíóòü ïîëíîñòüþ.
|
#413
|
||||
|
||||
Ïåðåâîæó ñòàòüþ ïî ïðèìåíåíèþ Äàçàòèíèáà ó ïàöèåíòîâ ñ õðîíè÷åñêèì ìèåëîëåéêîçîì. Ïîñêîëüêó ÿ íèêîèì îáðàçîì íå ãåìàòîëîã, èìåþ òðóäíîñòè ñ òî÷íûì ïåðåâîäîì íåêîòîðûõ òåðìèíîâ:
-complete cytogenetic response - ìîæíî ëè ïåðåâåñòè êàê "ÏÎËÍÛÉ öèòîãåíåòè÷åñêèé îòâåò"? òî æå ñàìîå äëÿ ñëåäóþùåãî òåðìèíà: - major molecular response - ÁÎËÜØÎÉ (?) ìîëåêóëÿðíûé îòâåò? È 2 ïîêàçàòåëÿ âûæèâàåìîñòè: -progression-free survival - âûæèâàåìîñòü áåç ïðîãðåññèðîâàíèÿ? - overall survival - âûæèâàåìîñòü â öåëîì (îáùàÿ âûæèâàåìîñòü)? Óìîì-òî ÿ ïîíèìàþ, î ÷åì ðå÷ü, à âîò êàê ýòî ïðàâèëüíî ñêàçàòü ïî-ðóññêè, íå çíàþ È åùå.  ñòàòüå óïîìèíàþòñÿ ñòàäèè ÕÌË: chronic è accelerated. Ïðàâèëüíî ëè íàçûâàòü èõ "õðîíè÷åñêàÿ" è "ïðîãðåññèðóþùàÿ" èëè ó ãåìàòîëîãîâ åñòü êàêàÿ-òî ñâîÿ òåðìèíîëîãèÿ? Çàðàíåå ñïàñèáî çà îòâåòû |
#414
|
||||
|
||||
Öèòàòà:
"ñòàäèÿ àêñåëëåðàöèè" òàê è ïðèìåíÿåòñÿ Öèòàòà:
|
#415
|
||||
|
||||
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#416
|
|||
|
|||
|
#418
|
|||
|
|||
Tract - based spatial statistics
(TBSS ) was used to analyze DTI data . TBSS allows group comparisons of dif f u s io n m ea s u r e s ( F A a n d M D) from t h e m o s t representative voxel w it h in major white matter tracts . Ýòî ïðî ÌÐÒ ãîëîâíîãî ìîçãà,íî êàê ýòî ïåðåâåñòè? |
#419
|
||||
|
||||
ÒÁÑÑ ïîçâîëÿåò ïðîâîäèòü ñðàâíåíèÿ ãðóïï äèôôóçíûõ èçìåðåíèé (...) îò íàèáîëåå ðåïðåçåíòàòèâíûõ ïàðàìåòðîâ (âîêñåëåé - îáüåìíûõ/òðåõìåðíûõ ïèêñåëåé) â ïðåäåëàõ ãëàâíûõ òðàêòîâ (îáðàçîâàíèé) áåëîé ìàòåðèè.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#420
|
||||
|
||||
ï.ñ.
êàê ïðåäïîëàãàþ, (F A a n d M D) = Fractional Anisotropy & MultiDimensional
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |